Correlation between sKL and Nrf2 plasma levels and calcium oxalate urolithiasis.

Publisher: Springer Country of Publication: Netherlands NLM ID: 0262521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2584 (Electronic) Linking ISSN: 03011623 NLM ISO Abbreviation: Int Urol Nephrol Subsets: MEDLINE

Publication: Amsterdam : Springer
Original Publication: Budapest, Akademiai Kiadó

Nephrolithiasis* ; Urinary Calculi*/metabolism ; Calculi* ; Kidney Calculi*/metabolism ; Urolithiasis*/metabolism; Humans ; Calcium Oxalate/metabolism ; Antioxidants ; Calcium

Objective: To investigate the relationship between plasma levels of sKL and Nrf2 and calcium oxalate calculi.
Methods: The clinical data of 135 patients with calcium oxalate calculi treated in the Department of Urology of the second affiliated Hospital of Xinjiang Medical University from February 2019 to December 2022, and 125 healthy persons who underwent physical examination in the same period were collected and divided into healthy group and stone group. The levels of sKL and Nrf2 were measured by ELISA. Correlation test was used to analyze the risk factors of calcium oxalate stones, logistic regression analysis was used to analyze the risk factors of calcium oxalate stones, and ROC curve was used to evaluate the sensitivity and specificity of sKL and Nrf2 in predicting urinary calculi.
Results: Compared with the healthy group, the plasma sKL level in the stone group decreased (111.53 ± 27.89 vs 130.68 ± 32.51), while the plasma Nrf2 level increased (300.74 ± 114.31 vs 246.74 ± 108.22). There was no significant difference in the distribution of age and sex between the healthy group and the stone group, but there were significant differences in plasma levels of WBC, NEUT, CRP, BUN, BUA, SCr, BMI, and eating habits. The results of correlation test showed that the level of plasma Nrf2 was positively correlated with SCr (r = 0.181, P < 0.05) and NEUT (r = 0.144 P < 0.05). Plasma sKL was not significantly correlated with Nrf2 (r = 0.047, P > 0.05), WBC (r = 0.108, P > 0.05), CRP (r = - 0.022, P > 0.05), BUN (r = - 0.115, P > 0.05), BUA (r = - 0.139, P > 0.05), SCr (r = 0.049, P > 0.05), and NEUT (r = 0.027, P > 0.05). Plasma Nrf2 was not significantly correlated with WBC (r = 0.097, P > 0.05), CRP (r = 0.045, P > 0.05), BUN (r = 0.122, P > 0.05), and BUA (r = 0.122, P > 0.05); (r = 0.078, P > 0.05) had no significant correlation. Logistic regression showed that elevated plasma sKL (OR 0.978, 95% CI 0.969 ~ 0.988, P < 0.05) was a protective factor for the occurrence of calcium oxalate stones, BMI (OR 1.122, 95% CI 1.045 ~ 1.206, P < 0.05), dietary habit score (OR 1.571, 95% CI 1.221 ~ 2.020, P < 0.05), and WBC (OR 1.551, 95% CI 1.423 ~ 1.424, P < 0.05). Increased NEUT (OR 1.539, 95% CI 1.391 ~ 1.395, P < 0.05) and CRP (OR 1.118, 95% CI: 1.066 ~ 1.098, P < 0.05) are risk factors for the occurrence of calcium oxalate stones.
Conclusion: Plasma sKL level decreased and Nrf2 level increased in patients with calcium oxalate calculi. Plasma sKL may play an antioxidant role in the pathogenesis of calcium oxalate stones through Nrf2 antioxidant pathway.
(© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)

Liu Y, Chen Y, Liao B et al (2018) Epidemiology of urolithiasis in Asia[J]. Asian J Urol 5(4):205–214. (PMID: 10.1016/j.ajur.2018.08.007303644786197415)
Maihemuti M, Du heng, Tuerhong D, et al (2017) Effect of Klotho protein on renal oxidative stress in rats with calcium oxalate nephrolithiasis. Chinese J Urol. 38(12):941–945.
Makoto K-O (2019) The Klotho proteins in health and disease. J Nat Rev Nephrol. 15:27–44. (PMID: 10.1038/s41581-018-0078-3)
Jian X, Joonho Y, Sung-Wan An et al (2015) Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 26:1150–1160. (PMID: 10.1681/ASN.2014040325)
Navarro-González Juan F, Dolores S-N, Javier D-C et al (2018) Effects of Pentoxifylline on soluble Klotho concentrations and renal tubular cell expression in diabetic kidney disease. J Diabetes Care 41:1817–1820. (PMID: 10.2337/dc18-0078)
Sivandzade F, Prasad S, Bhalerao A et al (2019) NRF2 and NF-қB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches[J]. Redox Biol 21:101059. (PMID: 10.1016/j.redox.2018.11.01730576920)
Meng X, Feng Y, Ying Le et al (2021) Klotho protects against diabetic kidney disease via AMPK- and ERK-mediated autophagy. Acta Diabetol. https://doi.org/10.1007/s00592-021-01736-4. (PMID: 10.1007/s00592-021-01736-433768379)
Bishop K, Momah T, Ricks J (2020) Nephrolithiasis[J]. Prim Care 47(4):661–671. (PMID: 10.1016/j.pop.2020.08.00533121635)
Wagner CA (2021) Etiopathogenic factors of urolithiasis. Factores etiopatogénicos de la urolitiasis. Arch Esp Urol 74(1):16–23. (PMID: 33459618)
Gao X, Sun Z, Ma G et al (2021) Reduced plasma levels of α-klotho and their correlation with klotho polymorphisms in elderly patients with major depressive disorders. Front Psychiatry. 12:682691. (PMID: 10.3389/fpsyt.2021.682691347210958548667)
He Q, Babcook MA, Shukla S et al (2016) Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model. Prostate 76(11):964–976. (PMID: 10.1002/pros.23185270406454946024)
Drew DA, Katz R, Kritchevsky S et al (2017) Association between Soluble Klotho and change in kidney function: the health aging and body composition study. J Am Soc of Nephrol. https://doi.org/10.1681/ASN.2016080828. (PMID: 10.1681/ASN.2016080828)
Ahmatjan B, Ruotian L, Rahman A et al (2023) Klotho inhibits the formation of calcium oxalate stones by regulating the Keap1-Nrf2-ARE signaling pathway. Int Urol Nephrol 55(2):263–276. (PMID: 10.1007/s11255-022-03398-936336747)
Chen WY (2020) Soluble Alpha-Klotho alleviates cardiac fibrosis without altering cardiomyocytes renewal. Int J Mol Sci 21(6):2186. (PMID: 10.3390/ijms21062186322357207139467)
Maltese G, Psefteli PM, Rizzo B et al (2017) The anti-ageing hormone klotho induces Nrf2-mediated antioxidant defences in human aortic smooth muscle cells. J Cell Mole Med. https://doi.org/10.1111/jcmm.12996. (PMID: 10.1111/jcmm.12996)
Wei C, Bin, et al (2018) Klotho protein inhibits H2O2-induced oxidative injury in endothelial Cells via regulation of PI3K/Akt/Nrf2/HO-1 Pathways. Can J Physiol Pharmacol. https://doi.org/10.1139/cjpp-2018-0277. (PMID: 10.1139/cjpp-2018-027728910549)
Lindberg K, Amin R, Moe OW et al (2014) The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol 25(10):2169–2175. (PMID: 10.1681/ASN.2013111209248542714178446)
Wolf M, An SW, Nie M et al (2014) Klotho Up-regulates Renal Calcium Channel Transient Receptor Potential Vanilloid 5 (TRPV5) by Intra- and Extracellular N-glycosylation-dependent Mechanisms. J Biol Chem. https://doi.org/10.1074/jbc.M114.616649. (PMID: 10.1074/jbc.M114.616649253783964276853)

81760128 Natural Science Foundation of Xinjiang

Keywords: Calcium oxalate stone; Nuclear factor erythroid-2-related factor2; Soluble klotho

2612HC57YE (Calcium Oxalate)
0 (Antioxidants)
SY7Q814VUP (Calcium)

Nephrolithiasis, Calcium Oxalate

Date Created: 20230517 Date Completed: 20230628 Latest Revision: 20230628

20231215

10.1007/s11255-023-03615-z

37198517